MAIA Biotechnology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 13 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 22 Mar 2027 |
Monitoring Framework
Key Performance Indicators
THIO-104 Phase 3 Patient Enrollment Quarterly29.0Target: 100 patients by year-end 2026
THIO-104 Activated Clinical Sites Quarterly34.0Target: Full global site activation
THIO-101 Phase 2 Expansion Active Sites Quarterly46.0Target: Broad global footprint (44 in Europe/Asia, 2 in US)
Watch Items
- THIO-104 Phase 3 Interim Survival AnalysisTrigger: Sufficient survival data collected in 2027Action: Conduct interim efficacy and safety analysis to support potential regulatory filings
- THIO-101 Phase 2 Expansion Interim Data ReadoutsTrigger: Enrollment milestones met in 3L NSCLC cohortAction: Evaluate Overall Response Rate (ORR) to support potential accelerated FDA approval filing
- Cash Runway and Burn RateTrigger: Cash reserves falling below 12 months of operating expensesAction: Assess additional capital requirements or strategic partnerships to sustain clinical development beyond Phase 3 completion
Research as of 19 Jun 2026